Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Inclusion Criteria:

* Age ≥18 years.
* Clinical and/or histopathologic diagnosis of LPP.
* Presence of scalp pruritus.
* Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1.
* Ability and willingness to provide written informed consent and comply with study procedures.
* Willingness to undergo optional scalp biopsy for research purposes.

Exclusion Criteria:

* Other forms of alopecia that may interfere with study assessments.
* Any systemic disease associated with hair loss.
* Inflammatory or infectious scalp disease that may interfere with the study.
* Any other conditions associated with pruritus.
* Prior use of nemolizumab.
* Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks).
* Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks).
* Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or
* biologics.
* Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks).
* Any other current treatments for hair loss (e.g., oral/topical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed.
* Allergy or hypersensitivity to nemolizumab or any excipients.
* Pregnancy or unwillingness to use highly effective contraception.
* Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.